Table 4

Patient outcomes

Control ASCT (n=5)IVTRD ASCT (n=4)EVTRD ASCT (n=5)
Days to neutrophil engraftment, median (range)11 (10–12)11 (11–13)10 (10–11)
Days to platelet engraftment, median (range)10 (10–11)10.5 (9–12)11 (10–14)
Grade 3/4 infections, n (%)2 (40)2 (50)4 (80)
Engraftment syndrome, n (%)0 (0)0 (0)1 (20)
Received consolidation, n (%)2 (40)2 (50)3 (60)
Received maintenance, n (%)4 (80)4 (100)5 (100)
Best response prior to ASCT, n (%)
 PR3 (60)1 (25)3 (60)
 VGPR1 (20)1 (25)1 (20)
 CR0 (0)1 (25)0 (0)
 sCR1 (20)0 (0)1 (20)
 sCR+flow MRD-negative0 (0)1 (25)0 (0)
Best response following ASCT, n (%)
 PR2 (40)0 (0)0 (0)
 VGPR0 (0)1 (25)0 (0)
 CR0 (0)0 (0)0 (0)
 sCR1 (20)2 (50)1 (20)
 sCR+flow MRD-negative2 (40)1 (25)4 (80)
  • ASCT, autologous stem cell transplant;CR, complete response; EVTRD, ex vivo regulatory T-cell depletion; IVTRD, in vivo regulatory T-cell depletion; MRD, minimal residual disease (depth between 10−4 and 10−5); PR, partial response; sCR, stringent complete response; VGPR, very good partial response.